Navigation Links
ONCOTHYREON APPOINTS JULIE M. EASTLAND AS CHIEF FINANCIAL OFFICER
Date:8/31/2010

SEATTLE, Aug. 31 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced the appointment of Julie M. Eastland as Chief Financial Officer and Vice President, Corporate Development, effective September 7, 2010. Ms. Eastland's responsibilities will include financial management, investor relations and business development.

"Ms. Eastland brings more than 25 years of financial management experience to Oncothyreon," said Robert L. Kirkman, M.D., President and CEO of Oncothyreon. "We are confident that this experience, coupled with her strategic planning and operational expertise in the biotechnology arena, will be an asset to our company, and we welcome her to our management team."

"I am delighted to join Oncothyreon and am looking forward to contributing to the company's development," said Ms. Eastland. "With the first interim look for the START trial of Stimuvax expected by year end, and with multiple Phase 2 trials for the PI-3 kinase inhibitor PX-866 being planned, it is an exciting time in Oncothyreon's history."

Ms. Eastland served as Chief Financial Officer and Vice President Finance and Operations of VLST Corporation, a privately-held biotechnology company, from February 2006 to 2010. From 2000 to 2005, Ms. Eastland held various finance positions at Dendreon Corporation, a publicly-traded biotechnology company, most recently as the Vice President of Strategic Planning. Prior to Dendreon, Ms. Eastland worked for Amgen, Inc. as area finance manager and assistant controller for its Colorado operations. Ms. Eastland has also worked as director of finance and planning for Encore Media Group, international finance and business manager and senior financial analyst for SCIENCE Magazine and financial manager for the Discovery Channel. Ms. Eastland received an M.B.A. from Edinburgh University Management School and a B.S. in finance from Colorado State University.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.

Forward-Looking Statements

This release contains statements that are forward-looking, including statements regarding Oncothyreon's expectations regarding clinical development activities. Although Oncothyreon believes that the forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. Forward-looking statements involve risks and uncertainties, many of which are beyond Oncothyreon's control. For a detailed description of such risks and uncertainties, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on U.S. EDGAR and in Canada on SEDAR. Oncothyreon does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Oncothyreon reports second quarter 2010 financial results
2. Oncothyreon announces second quarter 2010 financial results conference call
3. Oncothyreon announces presentations at upcoming investor conferences in June
4. Oncothyreon to present at the Rodman & Renshaw Annual Global Investment Conference
5. Oncothyreon reports full year and fourth quarter 2009 financial results
6. Oncothyreon reports first quarter 2010 financial results
7. Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
8. Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement
9. Oncothyreons PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover
10. Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
11. Oncothyreon announces webcast of third quarter 2009 financial results conference call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Feb. 12, 2016  BD (Becton, Dickinson ... medical technology company, today announced the launch of the ... Biology and Technology (AGBT) Meeting. ... enables genomic research by providing cost effective NGS library ... is a high-throughput, fully integrated, next generation sequencing (NGS) ...
(Date:2/11/2016)... , February 11, 2016 Non-profit ... Promote Genetic Understanding to Support Research and Discovery ... 100K, today announced an ambitious plan to sequence 100,000 individuals. ... Asian countries and at least 7 of North and East ... In the first phase, the project will focus on creating ...
(Date:2/11/2016)... HILDEN , Germany and ... QGEN ; Frankfurt Prime Standard: ... new QIAseq Targeted RNA Panels for gene expression profiling, ... next-generation sequencing (NGS). The panels enable researchers to select ... expression fold changes and discover interactions between genes, cellular ...
(Date:2/11/2016)... -- Wellcentive today announced it has been selected by FamilyCare ... community care organization (CCO) with more than 130,000 ... and care management solutions and services. Wellcentive,s capabilities ... managers, analysts and care managers while providing insight ... members. Oregon . ...
Breaking Biology Technology:
(Date:1/27/2016)... CHESTER, Ohio , Jan. 27, 2016  Rite ... supplier based in West Chester, Ohio ... their award winning service staff, based in ... technical capacity and ability to provide modifications, installations and ... John Dovalina , CEO of PLUS, commented, "PLUS has ...
(Date:1/25/2016)... Software, the world-leading supplier of image data management solutions ... data management solution OMERO Plus for the newly established ... Photo - http://photos.prnewswire.com/prnh/20160125/325328LOGO ... analysis measures the characteristics and behavior of cells, tissues ... as health and disease, the presence or absence of ...
(Date:1/22/2016)... , Jan. 22, 2016 ... the addition of the "Global Biometrics ... to their offering. --> ... the "Global Biometrics Market in Retail ... --> Research and Markets ...
Breaking Biology News(10 mins):